Navigation Links
Drug-like compound stops thyroid overstimulation in early NIH studies
Date:12/1/2010

Researchers at the National Institutes of Health have identified a compound that prevents overproduction of thyroid hormone, a finding that brings scientists one step closer to improving treatment for Graves' disease.

In Graves' disease, the thyroid gland never stops. Thyroid-stimulating antibodies bind to receptors, activating them to keep the thyroid hormone coming and coming like a broken traffic light stuck on green and causing the body problems in regulating energy, controlling other hormones and maintaining cells throughout the body.

Attacking the problem at its root cause, lead researcher Susanne Neumann, Ph.D., and her colleagues at the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) have identified a chemical compound that binds to the receptors and acts as an antagonist, keeping the stimulating antibodies from their work and potentially allowing the thyroid cells to revert to normal function.

The findings, published this month in the Journal of Clinical Endocrinology and Metabolism, establish the effect of the receptor antagonist on human thyroid cells. The antagonist has not yet been tested in animals or people and still has multiple steps of toxicology and safety testing before it may be ready for human trials.

Though treatments are available for hyperthyroidism caused by Graves' disease, including surgery, radioactive iodine, and antithyroid drugs, the relapse rates for these treatments are 5 percent, 21 percent and 40 percent, respectively, and each comes with unfavorable side effects.

"Our goal is to develop an easily produced, orally administered, safe and effective drug with few to no side effects that can be used in place of some of the more invasive treatments of hyperthyroidism caused by Graves' disease," said Marvin Gershengorn, M.D., chief of the Laboratory of Endocrinology and Receptor Biology within NIDDK's intramural research program and the senior author on the paper.

Graves' disease is an autoimmune disorder, causing the body's immune system to act against the body's own cells and organs. Graves' disease typically first occurs in people under 40 and affects approximately 1 percent of the U.S. population, with women five to 10 times more likely than men to have Graves' disease.

The newly discovered compound, which is a receptor antagonist, may have the added benefit of helping those with eye problems caused by Graves' disease called Graves' ophthalmopathy experienced by more than 25 percent of people with the disease. Eye problems may include painful swelling in the eye sockets, double vision, tears or itchy eyes, and protruding eyes with swollen eyelids that can't be easily shut, increasing the risk for eye diseases. Because the swelling in the eyes is thought to be associated with the same overstimulation of receptors caused by the same thyroid-stimulating antibodies as in the thyroid, the potential thyroid treatment may have the added benefit of treating the eye problems as well.

The Gershengorn team is also at work on the flip side of thyroid regulation. By researching the thyroid-stimulating hormone receptor, they're hoping to use drug-like compounds to stimulate this receptor to treat people with thyroid cancer, who need more stimulation of thyroid cancer cells to increase the efficacy of iodine radiation. They've tested their discovery in mice and hope to perform pre-clinical studies and to develop human trials in the foreseeable future.


'/>"/>

Contact: Amy F. Reiter
niddkmedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Source:Eurekalert

Related medicine news :

1. Compound shows promise against intractable heart failure
2. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
3. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
4. New pyrimidine compounds may lead to improved treatments for childhood brain cancer
5. Researchers find compound effective in destroying antibiotic-resistant biofilms
6. Compound enhances cancer-killing properties of agent in trials
7. Concentration, timing and interactions are key when it comes to dietary compounds
8. Breast cancer cells regulate multiple genes in response to estrogen-like compounds
9. Plant compound resveratrol shown to suppresses inflammation, free radicals in humans
10. Compounds in non-stick cookware may be associated with elevated cholesterol in children and teens
11. New investigational compound targets pancreatic cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global ... announced that Premier Research, a leading clinical development service provider, has selected ERT’s ... increasingly complex, due in part to an array of circumstances including the use ...
(Date:2/23/2017)... ... (PRWEB) February 23, ... the nation to come together to combine its favorite springtime ... its favorite fruit – apples! To celebrate National Nutrition Month, ... the “Apple Madness” bracket tournament – a five-week, five-round online ...
(Date:2/23/2017)... ... , ... HealthPostures, the desk for standing designer headquartered in Prior Lake, Minnesota ... Minneapolis Home and Garden Show which is being held February 24 through 26 and ... the Minneapolis Convention Center. , From its broad line of sit stand desk ...
(Date:2/22/2017)... NY (PRWEB) , ... February 22, 2017 , ... ... life and athletics. It’s enough to overwork even the sharpest brain. , Power ... offer peak healthy activity without over clocking the brain. Each capsule contains Cognizin® ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 According to a ... (X-ray Imaging Digital, Analog), MRI (Closed, Open), Ultrasound, CT, ... Oncology), End User (Hospitals, Imaging Centers) - Global Forecast ... global market over the forecast period of 2016 to ... Billion by 2021, at a CAGR of 6.6% from ...
(Date:2/23/2017)... The fast-growing cannabis market is expected ... . According to the 2017 Legal Marijuana Outlook, published ... create 283,422 jobs by 2020, with an implied growth rate ... years. The accelerating pace of cannabis legalization is considered as ... market, which will further create more business ventures and boost ...
(Date:2/23/2017)... Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company ... and market advanced products and therapies for the Wound ... sectors of healthcare, today announced its record results for ... 2016. Full Year 2016 Highlights are: ... full year 2015 revenue ...
Breaking Medicine Technology: